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ABSTRACT
Background: Pain, not responsive to opioid analgesics, remains a problem for patients with
chronic and cancer pain as well as their families, and clinicians. Opioid antagonists have var-
ious uses in pain and palliative care. Their use in the reversal of tolerance and hyperalgesia
remains at the basic science level and has limited linical exposure.
Objective: To improve symptom control and quality of life in patients with pain not re-
sponsive to opioid analgesics.
Design: Present three cases in which patients have undergone administration of opioid an-
tagonists for the purpose of analgesia.
Methods: Patients on opioids analgesics received parenteral opioid antagonist, naloxone.
Complete withdrawal under a sedative or conscious sedation was allowed and then the opi-
oid at smaller doses was restarted and analgesia was observed.
Results: All patients had improved analgesia on a significantly lower dose of opioid anal-
gesics. 
Conclusions: Only three patients who have received this procedure were presented yet all
have responded positively to this procedure. Further research is needed to elucidate the mech-
anism and clinical relevance in the acute use of opioid antagonists.
INTRODUCTION
PAIN FROM CANCER OR CANCER TREATMENT needsaggressive, immediate attention. Using the
World Health Organization (WHO) stepladder,1
90% of cancer pain is alleviated. A minority con-
tinue to have unmanageable pain. Patients with
previous or concurrent substance abuse often pre-
sent with pain intolerance and opioid tolerance.
Three cases of refractory pain altered with nalox-
one are presented. The response is thought pro-
voking and leads to many unanswered questions.
Opioid antagonists have various uses: detoxi-
fication, recidivism, and opioid toxicities from
respiratory suppression to constipation.3–6 In
rapid detoxification, intravenous naloxone is ad-
ministered to an opioid-dependent patient to
achieve opioid abstinence. Done under anesthe-
sia, it prevents discomfort and improves long-
term outcome in the dependent patient.7
In the setting of acute nociceptive postopera-
tive pain, naloxone with patient-controlled anal-
gesic (PCA) morphine failed to show decreases
in opioid requirements or increases in analge-
sia.8–10 The mechanism and responsiveness of
acute nociceptive and chronic pain are different.
Breitfeld et al.11 successfully used a drug holiday
to help an opioid-dependent and -tolerant patient
with cancer in pain. Drug holidays are used by
pain specialists for outpatients with refractory
chronic pain to reestablish analgesic responsive-
ness in an opioid dependent patient. A recent let-
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ter to the editor describes positive effects and dis-
cussion of an opioid antagonist concurrent with
methadone.12
Three cases in which naloxone “reset the re-
ceptors” in an opioid-tolerant patient with pain
and a case in which naloxone caused analgesia
are presented.
Case 1 involves a 47-year-old married man
with an acquired immunodeficiency syndrome
(AIDS)-defining diagnoses since 1985 and a his-
tory of back pain after a fall in 1977. He also has
a history of polysubstance abuse, antisocial be-
havior, a C3–5 fusion, and a L3–5 fusion. When
first seen in 1999, he was taking 2200 mg/d of
morphine along with an undetermined amount
of heroin. His pain was felt to be neuropathic
from AZT along with a secondary myofascial
pain and arthritic bone pain. Over the next 2
years, he underwent trials of calcitonin,
pamidronate, cyclobenzaprine, tizanidine, bac-
lofen, amitriptyline, amantadine, mexilitine, se-
lective serotonic reuptake inhibitors (SSRIs), and
methadone. The methadone was started at 240
mg daily and titrated to 800 mg daily. He regu-
larly rated his pain control at a 7.5–10 of 10. His
urine toxicology screens were regularly negative
for any substances other than methadone, yet on
several occasions, he used greater than his pre-
scribed amount of opioid analgesics.
After 4 months of discussion, he agreed to an
opioid receptor reversal with naloxone. He was
admitted to the hospital on 800 mg of methadone
with 3600 mg of morphine and 24 mg of hydro-
morphone per day. He received a total of 1.2 mg
of intravenous naloxone before any withdrawal
symptoms appeared. He continued in with-
drawal for approximately 20 minutes before opi-
oids were readministered. He was discharged
that day on 400 mg/d of methadone. On follow-
up 3 days later, he reported 4 of 10 pain with more
mobility in his back and a nonantaglic gait. Four
years later, he continues to require opioid anal-
gesics for persistent pain, although remembers
the procedure as helpful.
Case 2 involves a sober 44-year-old father with
a past history of intranasal heroin abuse presented
with obstructive pneumonia. He was found to
have a perihilar adenocarcinoma associated with
pain. He completed radiation treatment to the me-
diastinum, lung mass, left temporal lobe brain
metastases, and right ribs metastases. He also re-
ceived carboplatin and paclitaxel with palliative
radiation to his right sacroiliac joint and shoulder.
He was seen for poorly controlled cancer-related
neuropathic pain. His oral morphine was switched
to methadone, 50 mg four times daily, with
pamidronate, amitriptyline, tizanidine, and dexa-
methasone. He failed outpatient follow-up. A
month later, his oncologist restarted him on a reg-
imen of oral morphine 180 mg/d with gabapentin
600 mg three times daily, which produced som-
nolence and myoclonus. After reconsultation for
constant 10 of 10 pain, a methadone PCA, titrated
to 2.1 mg/hr produced 4 of 10 pain. He found the
pump cumbersome and chose to continue on oral
methadone. After admission to hospice, his med-
ication compliance and use of adjuvants (dexa-
methasone, compounded ketamine gel, mir-
tazepine, topiramate, and modafinil) improved.
Inpatient admission resulted in temporary and
modest relief on a hydromorphone PCA of 4.4
mg/hr with 2 mg rescues. He again rejected the
PCA and was discharged to home with “ade-
quate” 8 of 10 pain on oxycontin 180 mg three
times per day with methadone 20 mg for break-
through pain. His pain returned to an “intolera-
ble” 10 of 10. After 6 weeks of discussion, he
agreed to an opioid receptor reversal with nalox-
one. At home, 0.8 mg of intravenous naloxone re-
sulted in yawning, goosebumps, nausea, a bowel
movement, and a pain score of 0 of 10. He required
oxycodone for dyspnea and was stabilized on 40
mg of oxycontin daily. Four months later, still on
40 mg oxycontin, he died without physical pain.
Case 3 involves an 18-year-old with a history
of longer than 2 years of leiomyosarcoma that
presented on his adrenal gland. His sister had
died from leiomyosarcoma prior to his diagnosis,
so he and his family’s emotional response to this
diagnosis produced significant anxiety. He had
previously been seen by a pediatric anesthesiol-
ogist for his pain and presented to me after he
turned 18. NPO secondary to an espophageal
stricture, his medications included intrathecal
fentanyl, 900 g/d; 14 mg/d bupivicaine; and 472
g/d clonidine as well as parenteral sufentanil
19 g/hr with 29 g every 6 minutes as needed
and methadone, 30 mg twice daily. He was also
on 15 mg/hr midazolam with 15 mg every hour
as needed. His pain was secondary to hyperal-
gesia and anxiety. He was started on ultra-low-
dose naltrexone twice daily and mirtazepine and
had a brief period of improved symptoms. His
pain and nausea became worse when he was
switched from benzodiazepine to lorazepam at 3
mg/hr with 0.5 mg every hour as needed. After
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2 weeks, he agreed to come in for an opioid re-
ceptor reversal with naloxone. He was admitted
with a 9–10 of 10 pain but he expressed such fear
of this procedure that he requested sedation. Se-
dated per his request with profolol, intravenous
naloxone 0.6 mg resulted in a change in pupil
size, yawning, and involuntary defecation, then
a pain score of 0–2 of 10 pain with intrathecal fen-
tanyl at 1400 g/d, 21 mg/d bupivicaine, and 735
g/d clonidine. Upon discharge, the fentanyl
was changed to morphine and the bupivicaine
was reduced, although because of disease and
anxiety, he required extensive supportive care.
DISCUSSION
The reversal of opioid tolerance has been at-
tempted in a variety of ways. The simultaneous
administrations of opioids and N-methyl-D-as-
partate (NMDA) antagonists have had disap-
pointing results. Either the effect or side effects
have limited their success clinically. Crain and
Shen have looked at mu antagonism in other set-
tings. The animal studies on tolerance and depen-
dence13–18 and the failure to improve analgesia
with NMDA antagonists led to my first naloxone
experience in the 1990s. The results were pro-
found. I have used this technique on a series of
patients for refractory pain after serial trials of
opioids, adjuvants, procedures, and complemen-
tary techniques. These patients have tolerated the
acute discomfort of withdrawal to obtain im-
proved analgesia in less than 1 hour on approxi-
mately one third of the original opioid dose. Their
sensitivity to titration was renewed. The opioid
receptors appear to have “reset.” Case 1 had a
lasting effect, case 2 resulted in complete analge-
sia, and case 3 had tremendous analgesic dose re-
duction.
There is no literature on naloxone in patients
with chronic pain. Ultra-low-dose naltrexone is
described but the effect is limited and without
end point. The positive response with naloxone
demonstrates an incomplete understanding of
tolerance, analgesia, and hyperalgesia. Both pa-
tients had physiologic reasons for physical pain,
histories of substance abuse, and tolerance. Sim-
ilarly, tolerance and/or hyperalgesia do not ade-
quately explain the reversal of symptoms in case
2. The combination of mechanisms may explain
symptom improvement and/or opioid dose re-
duction but not pain elimination. The exact mech-
anism remains unclear. Hypotheses in animals
that best correlate with GM1 ganglioside effects,
but those the discussions have remained at the
basic science level.19–23 Exploration in a con-
trolled clinical setting is warranted to further un-
derstand the mechanism and possible clinical role
of opioid antagonists in the treatment of refrac-
tory chronic and cancer pain.
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